Tag Archive for: Verona Pharma

Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD

LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces additional exacerbation* subgroup analyses from the Phase 3 ENHANCE-2 (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) trial in chronic obstructive pulmonary disease (“COPD”). Top-line results from the trial are available on Verona Pharma’s […]

A Q&A by Verona Pharma ahead of World Lung Cancer Day

This World Lung Day, Verona Pharma is raising awareness of the debilitating burden of respiratory diseases, most specifically Chronic Obstructive Pulmonary Disease (COPD), which affects more than 384 million patients and is the third leading cause of death worldwide. What is COPD and what are the current treatments available to those patients suffering with progressive […]

Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD

Statistically significant improvements in key measures of lung function 42% reduction in rate of exacerbations over 24 weeks Well tolerated with safety results similar to placebo Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or […]